Pharmaceutical Industry Information Portal

HomeTagsNanolek

All posts by tag

Nanolek

Gennady Schweigert and Pavel Mileiko acquire 50% stake in Nanolek LLC

Nanolek LLC informs about changes in the ownership structure: K2 Group, previously holding a 50% of the company, has divested its interest, transferring it...

Vladimir Khristenko resigns as President of Nanolek

Co-founder of Nanolek Vladimir Khristenko announced his intention to step down as President, the post he has been holding since 2015. Mr. Khristenko transferred...

NANOLEK began industrial production of the CoviVac vaccine

NANOLEK announced the launch of industrial production of CoviVac. Investments in this project amounted to 40 million rubles, the company said. The manufacturer plans...

All the four national vaccines are produced rhythmically in line with the plans

Russia has put into circulation about 32 million sets of coronavirus vaccines since the beginning of the year, and new sites are joining in...

Positive results were obtained for the drug Zanubrutinib in a comparative trial with Isrutinib

Brukinsa® (zanubrutinib) is under regulatory review for relapsed, refractory MCL in the Russian Federation with potential approval at the end of the 2021.

NANOLEK will invest 5 billion rubles in the full production cycle

Nanolek, a biopharmaceutical company, announces a plan to invest 5 billion rubles over 3 years in its full-cycle vaccine production facility in the Kirov region and an R&D Center for Biotech Medicines in Moscow.
spot_img

Expert Articles

spot_img